title: Oats to children with newly diagnosed coeliac disease: a randomised double blind study.
abstract: BACKGROUND
  Treatment of coeliac disease (CD) requires lifelong adherence to a strict gluten free diet (GFD) which hitherto has consisted of a diet free of wheat, rye, barley, and oats. Recent studies, mainly in adults, have shown that oats are non-toxic to CD patients. In children, only open studies comprising a small number of patients have been performed.
  
  
  OBJECTIVE
  To determine if children with CD tolerate oats in their GFD.
  
  
  METHODS
  In this double blind multicentre study involving eight paediatric clinics, 116 children with newly diagnosed CD were randomised to one of two groups: one group was given a standard GFD (GFD-std) and one group was given a GFD with additional wheat free oat products (GFD-oats). The study period was one year. Small bowel biopsy was performed at the beginning and end of the study. Serum IgA antigliadin, antiendomysium, and antitissue transglutaminase antibodies were monitored at 0, 3, 6, and 12 months.
  
  
  RESULTS
  Ninety three patients completed the study. Median (range) daily oat intake in the GFD-oats group (n = 42) was 15 (5-40) g at the six month control and 15 (0-43) g at the end of the study. All patients were in clinical remission after the study period. The GFD-oats and GFD-std groups did not differ significantly at the end of the study regarding coeliac serology markers or small bowel mucosal architecture, including numbers of intraepithelial lymphocytes. Significantly more children in the youngest age group withdrew.
  
  
  CONCLUSIONS
  This is the first randomised double blind study showing that the addition of moderate amounts of oats to a GFD does not prevent clinical or small bowel mucosal healing, or humoral immunological downregulation in coeliac children. This is in accordance with the findings of studies in adult coeliacs and indicates that oats, added to the otherwise GFD, can be accepted and tolerated by the majority of children with CD.
authors.affiliation: Department of Paediatrics, Norrköping Hospital, Sweden. lotta.hogberg@lio.se
authors.forename: L
authors.initials: L
authors.lastname: Högberg
authors.forename: P
authors.initials: P
authors.lastname: Laurin
authors.forename: K
authors.initials: K
authors.lastname: Fälth-Magnusson
authors.forename: C
authors.initials: C
authors.lastname: Grant
authors.forename: E
authors.initials: E
authors.lastname: Grodzinsky
authors.forename: G
authors.initials: G
authors.lastname: Jansson
authors.forename: H
authors.initials: H
authors.lastname: Ascher
authors.forename: L
authors.initials: L
authors.lastname: Browaldh
authors.forename: J-A
authors.initials: JA
authors.lastname: Hammersjö
authors.forename: E
authors.initials: E
authors.lastname: Lindberg
authors.forename: U
authors.initials: U
authors.lastname: Myrdal
authors.forename: L
authors.initials: L
authors.lastname: Stenhammar
mesh_terms: D000293:Adolescent; D001323:Autoantibodies / Q000097:blood; D018554:Avena; D002446:Celiac Disease / Q000097:blood / Q000178:diet therapy* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D005903:Gliadin / Q000276:immunology; D005983:Glutens / Q000008:administration & dosage; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007223:Infant; D007413:Intestinal Mucosa / Q000473:pathology; D008297:Male; D018485:Muscle Fibers, Skeletal / Q000276:immunology; D011503:Transglutaminases / Q000276:immunology
chemical_list: D001323:Autoantibodies; D007070:Immunoglobulin A; D005983:Glutens; D005903:Gliadin; D011503:Transglutaminases